Page 145 - CW E-Magazine (1-10-2024)

Pharmaceuticals

PLI SCHEME
Potassium clavulanate fermentation unit begins

commercial production

India’s fi rst unit to produce the rently met by imports from China and tion on stamp duty and registration fee,
active pharmaceutical ingredient (API), Korea. besides subsidised land at the rate of
potassium clavulanate, has commenced Re 1 per sq.m. The centrally-funded PLI
large-scale production in the last few The state-level Single Window programme was launched for the pro-
weeks. Clearance and Monitoring Authority motion of domestic manufacturing of
had approved the project in its 17th critical key starting materials (KSMs)/
Set up under the centrally-spon- meeting on July 7, 2021. The in-princi- drug intermediates and APIs in the
sored Production Linked Incentive pal approval for setting up the plant country few years ago. It was launched
(PLI) scheme, this fermentation plant was issued on July 28 the same year. after wide-ranging deliberations on
at Plassra in Nalagarh (Himachal India’s dependence on critical resources,
Pradesh) unit has a capacity to pro- The unit has also benefi tted from a risk to supply chain bottlenecks
duce 400-tpa of potassium clavula- several special incentives. These after COVID pandemic disrupted supply
nate. The domestic demand of the include 100% exemption on electricity chains. The government had identifi ed
API is pegged at 700 tonnes per duty for fi ve years, 15% rebate on energy 48 critical APIs for local manufacturing
annum, and the entire demand is cur- charges for fi ve years, 100% exemp- in its fi rst initiative.

FOCUS ON SUSTAINABILITY
Piramal Pharma’s GHG commitment validated

and approved by SBTi

Piramal Pharma has embarked on ing with global climate United Nations Global
its sustainability journey as the Science action goals. To further Compact (UNGC),
Based Targets initiative (SBTi) offi cially reinforce our commit- World Resources Insti-
validated the company’s near-term ment, we are also in tute (WRI) and World
greenhouse gas (GHG) emission reduc- the process of deve- Wildlife Fund (WWF),
tion targets. loping a comprehensive guides companies in
Carbon Reduction Plan, which will be reducing their GHG emissions. It pro-
The company has committed to re- unveiled soon. While we have come a vides a clear pathway for future-proof
duce absolute scope 1 and 2 GHG emis- long way, in many respects, our sus- growth by specifying how much and
sions 42% by FY2030 from a FY2022 tainability journey is just beginning.” how quickly emissions must be cut to
base year. Piramal Pharma has also The SBTi, a collaboration between limit global warming to well below
committed to reduce absolute scope 3 the Carbon Disclosure Project (CDP), 1.5°C above pre-industrial levels.
GHG emissions from purchased goods
and services, fuel and energy related USFDA completes inspection at
activities, upstream transportation and
distribution and use of sold products Dr. Reddy’s Bachupally R&D centre
25% within the same timeframe. This
makes Piramal Pharma the third global Dr. Reddy’s Labs has informed The inspection was conducted from
pharmaceutical company in India to that the USFDA has completed a September 16-20, 2024. Dr. Reddy’s
receive approval from the SBTi. routine Good Manufacturing Practice had earlier received the Establish-
Ms. Nandini Piramal, Chairperson, Piramal (GMP) inspection at its R&D centre ment Inspection Report (EIR) from
Pharma, said, “The approval from SBTi (Integrated Product Development the USFDA for the formulations
reinforces our ongoing commitment to Organisation or IPDO) in Bachupally, manufacturing facility (FTO-3) in
reducing our GHG emissions and align- Hyderabad with zero observations. Bachupally.

Chemical Weekly October 1, 2024 145

Contents Index to Advertisers Index to Products Advertised